Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon, Agendia Ink Clinical Supply Pact

NEW YORK (GenomeWeb News) – Rubicon Genomics said today that molecular diagnostics company Agendia will use Rubicon's whole-genome RNA amplification technology with Agendia's breast cancer diagnostic tests.

Under a clinical supply agreement, Agendia will incorporate Rubicon's TransPlex technology into the analysis of formalin fixed, paraffin-embedded patient samples for use in testing with its Symphony suite of breast cancer diagnostics.

Ann Arbor, Mich.-based Rubicon said its TransPlex kits are aimed at improving the quality and quantity of nucleic acids extracted from FFPE samples to enable accurate and consistent analysis of molecular diagnostic tests.

In a statement, Rubicon CEO James Koziarz called the deal an important milestone for his firm. "This supply agreement with cancer diagnostics pioneer Agendia represents our first large-scale commercial partnership with a provider of clinical diagnostic tests, and we expect it to be the first of many going forward," he said.

Financial and other terms of the deal were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.